However, with the approval of trastuzumab for the treatment of metastatic/unresectable GC/GEJ tumours and the recent approval of antibody-drug conjugates like trastuzumab deruxtecan, there exist multiple therapeutic options associated with improved efficacy for the treatment of HER2/neu-positive advanced GC tumours [12,13]. Here, ERBB2 is linked to gastric cancer.